Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine DOI Creative Commons
Saif Khan,

Suresh Babu Jandrajupalli,

Nashwa Zaki Ali Bushara

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(24), P. 2126 - 2126

Published: Dec. 22, 2024

Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors PARP offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug conjugates (ADCs) sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with Trop-2-targeting antibody via pH-sensitive linking moiety, achieving good drug:antibody ratio. In phase I-II study involving metastatic TNBC (mTNBC) individuals, achieved overall response rate 33.3% median period 7.7 months. The III ASCENT trial demonstrated SG’s efficacy in relapsed or refractory TNBC, improving progression-free survival compared chemotherapy. Common side effects include neutropenia, nausea, fatigue. This article highlights clinical potential, pharmacokinetics, safety profile, resistance mechanisms along key ongoing trials, emphasizing role managing mTNBC, especially third-line therapy. review also discusses current strategies for adverse reactions sequencing ADC treatments practice, predicted basis resistance. optimal relative other ADCs, such as trastuzumab deruxtecan T-DXd, evolving question, newer agents distinct action profiles enter field. Further research is essential establish evidence-based addressing disease progression post-ADC

Language: Английский

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms DOI Creative Commons
Aditi Jain,

Alan Barge,

Christopher N. Parris

et al.

Oncogene, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 21, 2024

Abstract Triple-negative breast cancer (TNBC) is a particularly aggressive subtype, characterised by higher incidence in younger women, rapid metastasis, and generally poor prognosis. Patients with TNBC BRCA mutations face additional therapeutic challenges due to the cancer’s intrinsic resistance conventional therapies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have emerged as promising targeted treatment for BRCA-mutated TNBC, exploiting vulnerabilities homologous recombination repair (HRR) pathway. However, despite initial success, efficacy of PARPis often compromised development mechanisms, including HRR restoration, stabilisation replication forks, reduced PARP1 trapping, drug efflux. This review explores latest breakthroughs overcoming PARPi through combination These strategies include integration chemotherapy, immunotherapy, antibody-drug conjugates, PI3K/AKT pathway inhibitors. combinations aim enhance targeting multiple progression pathways. The also discusses evolving role within broader paradigm emphasising need ongoing research clinical trials optimise strategies. By tackling associated exploring novel therapies, this sheds light on future possibilities improving outcomes patients TNBC.

Language: Английский

Citations

6
Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment DOI
Rahaman Shaik,

V. Pavani Sai Mounika,

S. Begum

et al.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

One of the most potent therapeutic and diagnostic agents in contemporary medicine is monoclonal antibody (mAb). mAbs can perform a variety tasks breast cancer (BC), including identifying delivering medications to targets, preventing cell development, suppressing immune system inhibitors directly attacking cells. are one effective options, particularly for HER2, but they have not been well studied their use treating other forms BC, triple negative tumors. Bispecific trispecific created new opportunities more targeted specific efficacy, which has positive impact on viability antigen specificity. They versatile than treatment, emerging as popular option BC. However, limit treatment due certain adverse effects, fever, shaking, exhaustion, headache, nausea, vomiting, rashes, bleeding, difficulty breathing. To examine current prospective future capacities with regard detection present review highlights advantages disadvantages mAb approach.

Language: Английский

Citations

0
ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC DOI
Bo Luo, Xiangdong Liu, Qu Zhang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 140, P. 112875 - 112875

Published: Aug. 9, 2024

Language: Английский

Citations

1
The Revolution in Breast Cancer Diagnostics: From Visual Inspection of Histopathology Slides to Using Desktop Tissue Analysers for Automated Nanomechanical Profiling of Tumours DOI Creative Commons
Martin Stolz

Bioengineering, Journal Year: 2024, Volume and Issue: 11(3), P. 237 - 237

Published: Feb. 28, 2024

We aim to develop new portable desktop tissue analysers (DTAs) provide fast, low-cost, and precise test results for fast nanomechanical profiling of tumours. This paper will explain the reasoning choosing indentation-type atomic force microscopy (IT-AFM) reveal functional details cancer. Determining subtype, cancer stage, prognosis be possible, which aids in best treatment. DTAs are based on IT-AFM at size a small box that can made low budget compared other clinical imaging tools. The work remote areas all parts world. There number direct benefits: First, it is no longer needed wait week pathology report as only take 10 min. Second, avoids complicated steps making histopathology slides saves costs labour. Third, computers robots more consistent, reliable, economical than human workers may result fewer diagnostic errors. Fourth, analysis capable distinguishing between various subtypes. Fifth, could insights about why immunotherapy fails. Sixth, into neoadjuvant treatment response. Seventh, healthcare system money by reducing backlogs. Eighth, stored central server accessed strategies prevent To bring technology from bench operation theatre, sensor needs developed integrated DTAs.

Language: Английский

Citations

0
Recent advances targeting chemokines for breast cancer DOI

Yanan Zhang,

Xiufeng Tang, Ying Wang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 146, P. 113865 - 113865

Published: Dec. 22, 2024

Language: Английский

Citations

0
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine DOI Creative Commons
Saif Khan,

Suresh Babu Jandrajupalli,

Nashwa Zaki Ali Bushara

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(24), P. 2126 - 2126

Published: Dec. 22, 2024

Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors PARP offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug conjugates (ADCs) sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with Trop-2-targeting antibody via pH-sensitive linking moiety, achieving good drug:antibody ratio. In phase I-II study involving metastatic TNBC (mTNBC) individuals, achieved overall response rate 33.3% median period 7.7 months. The III ASCENT trial demonstrated SG’s efficacy in relapsed or refractory TNBC, improving progression-free survival compared chemotherapy. Common side effects include neutropenia, nausea, fatigue. This article highlights clinical potential, pharmacokinetics, safety profile, resistance mechanisms along key ongoing trials, emphasizing role managing mTNBC, especially third-line therapy. review also discusses current strategies for adverse reactions sequencing ADC treatments practice, predicted basis resistance. optimal relative other ADCs, such as trastuzumab deruxtecan T-DXd, evolving question, newer agents distinct action profiles enter field. Further research is essential establish evidence-based addressing disease progression post-ADC

Language: Английский

Citations

0